Skip to content

PolitiKit

Brigitte Nolet's lobbying: the registrations they file and every meeting they've reported since November 2021.

← Lobbying

Registrant (responsible officer)

Brigitte Nolet

PRESIDENT AND CHIEF EXECUTIVE OFFICER

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Meetings this Parliament
11
Since Nov 2021
114
Active registrations
0

Reported meetings

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
    • Marjorie Michel · Minister of Health
    • Karim Bardeesy · Member of Parliament
    • Janice Charette · Chief Trade Negotiator to the United States, House of Commons
    and 7 more
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada, Global Affairs Canada (GAC)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
    Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Read more

    Official report

  • Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry

    Official report

  • Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry

    Official report

    • Karim Bardeesy · Parliamentary Secretary Assistant, Innovation, Science and Economic Development Canada (ISED)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 5 more
    • Chase Knight · Parliamentary Secretary Assistant and Parliamentary Affairs Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Victoria Morton · Senior Communications Advisor, House of Commons
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry

    Official report

    • Greg Orencsak · Deputy Minister, Health Canada (HC)
    • Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
    Health Canada/PMPRB proposed regulation changes to the Patented Medicines Regulations.

    Official report

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry

    Official report

  • Clinical Trials environment in Canada: operational issues, investment, enrollment

    Official report

  • and 3 more
    Clinical Trials environment in Canada: operational issues, investment, enrollment

    Official report

    • Manuela Tomic · Senior ADvisor, Innovation, Science and Economic Development Canada (ISED)
    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Official report

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Official report

    • David Lee · Chief Regulatory Officer, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • Patrick Wittmann · Ambassador of Canada to Switzerland and Liechtenstein, Global Affairs Canada (GAC)
    • Nadja Schauer · Counsellor (Commercial) and Senior Trade Commissioner, Global Affairs Canada (GAC)
    • Matthew Peters · Head of Investment, Global Affairs Canada (GAC)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    and 8 more
    • Jocelyn Milburn · Director, Innovation, Science and Economic Development Canada (ISED)
    • Stacey Mantha · Interim Director General (Representing Stephen Bent), Public Health Agency of Canada (PHAC)
    • Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
    • Heather Deehan · Director, Public Health Agency of Canada (PHAC)
    • Cheryl Marinsky · Policy Analyst, Public Health Agency of Canada (PHAC)
    • Andrea Knight · Special Advisor, HERC, Innovation, Science and Economic Development Canada (ISED)
    • Fern Bannatyne · Associate Director, Public Health Agency of Canada (PHAC)
    • Sylvain Roussel · Acting Director, Health Canada (HC)
    Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade, establishment of an approval framework for subsequent entry biologic products, provision of data exclusivity for innovative drug products, review and approval of new drug submissions and post market surveillance of drug products and/or data protection and the regulation and protection of biopharmaceutical products. Read more

    Policies related to the importation of pharmaceuticals from Canada to the United States

    Official report

    • Sarah Lawley · ADM, Health Canada (HC)
    • Sarah Lawley · ADM, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
    Policies related to the importation of pharmaceuticals from Canada to the United States

    Official report

  • House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee Read more

    Official report

    • Jennings Phillip · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Official report

    • Tanya Ramsamy · Director, PDD, Health Canada (HC)
    • Martin McLean · Director, PDD, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • Tanya Ramsamy · Director, PDD, Health Canada (HC)
    • Martin McLean · Director, PDD, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • David Lee · Chief Regulatory Officer, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • Eshan Naik · Director of Policy, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • Eshan Naik · Director of Policy, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • Lee David K · Chief Regulatory Office, Health Product and Food Branch, Deputy Minister's Office, Health Canada (HC)
    • Alysha Croker · Director, BRDD, Centre for Policy, Pediatrics and International Collaboration, Health Canada (HC)
    • Patricia Dechman · Acting Associate Director, Policy, Planning & International Affairs Directorate, Health Canada (HC)
    Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process

    Official report

    • Sophie Sommerer · Director General, BRDD (Biologics and Radiopharmaceutical Drug Directorate), Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
    • Joyce Boye · Director General, Food & Nutrition Directorate, Health Canada (HC)
    • Ed Morgan · Director General, Policy Planning & International Affairs Directorate, Health Canada (HC)
    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Official report

    • Melisssa Sutherland · A/ Director General, Health Canada (HC)
    • Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
    • Greg Orencsak · Deputy Minister of Health, Health Canada (HC)
    Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries

    Official report

    • Jeannine Ritchot · Assistant Deputy Minister, Privy Council Office (PCO)
    Strategic Innovation Fund, as it relates to any initiative submitted or supported

    Official report

    • Elizabeth Troller · Director General, Health Care Strategies, Health Canada (HC)
    • Jessica Thomson · Senior Policy Analyst, Health Canada (HC)
    Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.